Categories
Livemint news News in India

High level Central teams to monitor Covid-19 in 5 states – News in India by Post24x7

2020-10-16 14:35:00
Coronavirus

New Delhi: Centre on Friday has deputed high level Central teams to five states who are struggling the most with the Covid-19 outbreak. The states are Kerala, Karnataka, Rajasthan, Chhattisgarh and West Bengal. These states have been reporting a surge in the number of new Covid-19 cases in the recent days, said Ministry of Health and Family Welfare in an official release.

Each team comprises of a Jt. Secretary (nodal officer for the respective State), one public health expert to look after the public health aspects, one clinician to look after infection prevention practices, clinical management protocol being followed by the State.

The teams will support the State efforts towards strengthening containment, surveillance, testing, infection prevention and control measures, and efficient clinical management of the positive cases. The Central teams shall also guide in effectively managing the challenges related to timely diagnosis and follow up.

The total cases in Kerala are 3,17,929 which form 4.3% of the total cases. The cases per million stand at 8906. Total number of recovered cases is 2,22,231 accounting for recovery rate of 69.90%. The active cases are 94,609 (comprising 11.8% of the total national figure). Total deaths in the state are 1,089 with Case Fatality Rate of 0.34% and deaths per million of 31. The TPM of Kerala stand at ,and positivity rate is 16.6%.

Karnataka is reporting 7,43,848 total cases accounting for 10.1% of the national figure. It has 11,010 cases per million population. 6,20,008 patients have recovered in the state resulting in recovery rate of 83.35%. The active cases are 1,13,557 (14.1% of national figure). The state has reported total of 10,283 fatalities, CFR of 1.38% and 152 Deaths per Million population. The TPM is 95674 and Positivity Rate is pegged at 11.5%.

Rajasthan has registered 1,67,279 total cases (% share in total: 2.3%), 2,064 Cases Per million and 1,43,984 total number of recoveries with Recovery Rate of 86.07%. The active cases as on date are 21,587 (2.7% share in the national numbers). The numbers of fatalities in the State is 1,708; Case Fatality Rate is 1.02%; and Deaths Per Million stands at 21. TPM is 38,605 with Positivity Rate of 5.3%.

West Bengal has 3,09,417 Total Cases (4.2% of the national cases) amounting to 3,106 Cases Per million population. Total Recovered are 2,71,563 and the Recovery Rate is 87.77%. With 31,984 Active Cases, the State accounts for 4.0% of the total pie. Total Deaths are 5,870; Case Fatality Rate is 1.90% whereas the Deaths per Million population are 59. 37,872 TPM, the Positivity Rate is 8.2%.

Chhattisgarh is reporting 1,53,515 Total Cases (% Share in Total Cases – 2.1%), 5,215 Cases per Million, 1,23,943 Total Recovered and 80.74% Recovery Rate. It has 28,187 Active Cases comprising 3.5% of the national figure. There have been 1385 Total Deaths in the State accounting for Case Fatality Rate of 0.90% and 47 Deaths Per Million. The TPM are 50191 and Positivity Rate is 10.4%.

As an ongoing effort to strengthen efforts of various State/UT Governments for COVID management, the Central Government has been deputing Central teams from time to time to visit various States/UTs. These teams will interact with the State/UT authorities and get a first hand understanding of the challenges and issues being faced by them so as to strengthen their ongoing activities and remove bottlenecks, if any.

Subscribe to Mint Newsletters

* Enter a valid email

* Thank you for subscribing to our newsletter.

Read more

Categories
Livemint news News in India

India reports 63,371 new covid cases, 70338 recoveries in a day – News in India by Post24x7

2020-10-16 10:13:00
Coronavirus

India’s COVID-19 tally of cases climbed to 73.70 lakh with 63,371 new cases in a day, while 64,53,779 people have recuperated so far pushing the national recovery rate to 87.56% per cent on Friday, according to the Union Health Ministry data.

The total coronavirus cases mounted to 73,70,469 and the death toll climbed to 1,12,161 with the novel coronavirus virus claiming 895 lives in a span of 24 hours in the country, the data updated at 8 am showed.

The COVID-19 case fatality rate has further declined to 1.52 per cent.

There are 80,45,28 active cases of coronavirus infection in the country which comprises 11.11 per cent of the total caseload, the data stated.

According to the ICMR,10,28,622 samples were tested for COVID-19 yesterday. Total 9,22,54,927 samples tested in the country up to October 15

Subscribe to Mint Newsletters

* Enter a valid email

* Thank you for subscribing to our newsletter.

Read more

Categories
Livemint news News in USA

US coronavirus cases surpass 8 million as infections spike nationwide – News in USA by Post24x7

2020-10-16 06:23:00
Coronavirus

US cases of the novel coronavirus crossed 8 million on Thursday, rising by 1 million in less than a month, as another surge in cases hits the nation at the onset of cooler weather.

Since the pandemic started, over 217,000 people have died in the United States.

The United States reported 60,000 new infections on Wednesday, the highest since Aug. 14, with rising cases in every region, especially the Midwest.

Health experts have long warned that colder temperatures driving people inside could promote the spread of the virus. They have not pinpointed the reason for the rise but point to fatigue with COVID-19 precautions and students returning to schools and colleges.

According to a Reuters analysis, 25 states have so far set records for increases in new cases in October. (Graphic: https://tmsnrt.rs/2SFLb7o)

All Midwest and Northeast states have reported more cases in the past four weeks than in the prior four weeks, with the number of new cases doubling in states like Wisconsin, South Dakota and New Hampshire.

In the Midwest, daily new cases hit a record on Wednesday with over 22,000 new infections. The positive test rate tops 30% in South Dakota and 20% in Idaho and Wisconsin.

Ten states on Thursday reported record increases in new cases, including Wisconsin with 4,000 new cases. “Our numbers are high and they’re growing rapidly,” state Health Secretary-Designate Andrea Palm told a news conference.

“We have now surpassed 1,000 COVID-19 patients who are in the hospital. In some regions of our state, our ICU beds are 90% or more full. Over the course of the past six weeks, our average daily deaths have more than tripled,” Palm added.

California remains the state with the most total cases followed by Texas, Florida, New York and Georgia. Those five states account for over 40% of all reported COVID-19 cases in the nation.

With both cases and positive test rates rising in recent weeks, New York City has closed businesses and schools in neighborhood hot spots despite protests from a small contingent of Orthodox Jews.

In addition to rising cases, hospitals in several states are straining to handle an influx of patients.

In the Midwest, COVID-19 hospitalizations hit a record high for a tenth day in a row on Wednesday. Nationally, the United States reported nearly 37,000 hospitalizations, the highest since Aug. 28.

Wisconsin, which reported record hospitalization on Wednesday, has opened a field hospital outside of Milwaukee to handle COVID-19 patients.

Subscribe to Mint Newsletters

* Enter a valid email

* Thank you for subscribing to our newsletter.

Read more

Categories
Livemint news News in India

Why Trump’s covid-19 antibody cocktail won’t be widely available – News in India by Post24x7

2020-10-15 17:21:00
Coronavirus

The antibody cocktail US President Donald Trump credited for his swift coronavirus recovery won’t become widely available because it’s impossible to make enough for everyone who might need it, according to the Swiss pharmaceutical giant working on scaling up production.

“We’ll never be able to produce enough,” said Bill Anderson, drugs chief at Roche Holding AG, which is working together with US biotech Regeneron Pharmaceuticals Inc. on the project. “This is clearly part of the answer for the world, not the answer. Hopefully we’ll have vaccines and other therapeutics.”

The partners will probably be able to make as many as 2 million doses per year by the end of next March if the drug cocktail wins regulatory approval, Anderson said. That’s about the number of new Covid-19 cases identified worldwide in the past week.

The need for a multipronged approach to treat the virus has come into focus as potential safety issues emerge in late-stage trials of some promising vaccines and treatments. Eli Lilly & Co. this week paused a study of its own Covid-19 antibody to investigate such a concern.

Roche on Thursday reported third-quarter sales that fell short of estimates after a one-two punch: older prescription drugs faced a challenge from cheaper copycats while the pandemic continued to discourage some patients from seeing their doctors. The stock fell as much as 3.6% in Zurich trading.

Big dose

The US has already secured hundreds of thousands of doses of experimental antibody treatments, federal health officials said earlier this month, before the Lilly trial was paused. At that point they expected to have 1 million doses on hand by the end of the year.

Trump touted Regeneron’s antibody cocktail as a cure and key to his recovery, saying he would make the drugs he took available for free to Americans. Regeneron has asked federal regulators for emergency clearance to sell the treatment. Though the drug had promising early results, the large clinical trials to test its safety and efficacy haven’t finished yet.

Production capacity is limited in part because the antibody doses being studied for Covid-19 are so much bigger than for other diseases, according to Roche’s Anderson. For example, the low dose being evaluated in Regeneron’s trial, 2.4 grams, is about as much antibody as is used to treat a breast cancer patient for four to six months or a person with multiple sclerosis for two years, he said.

Subscribe to Mint Newsletters

* Enter a valid email

* Thank you for subscribing to our newsletter.

Read more

Categories
Livemint news News in India

Delhi cinema halls reopen from tomorrow: Here is all you need to know – News in India by Post24x7

2020-10-14 10:33:00
Coronavirus

All cinema halls, theatres and multiplexes are allowed to function from tomorrow (15 October) in Delhi, but with a limited seating capacity. “Cinemas will be allowed to reopen in Delhi from 15 October. They will have to follow all the guidelines laid out by the central government,” chief minister Arvind Kejriwal had earlier said along with announcing reopening permits for weekly markets.

In Delhi, cinema halls, multiplexes and theatres have been shut since March 12 to check the spread of the coronavirus disease.

Earlier, the Information and Broadcasting Ministry had released the standard operating procedures (SOPs) for cinema halls and theatres to open across the country.

Here are the guidelines for reopening movie theatres:

-Occupancy of the auditorium shall not be more than 50%

-Adequate physical distancing while seating

-Seats ‘Not to be occupied’ shall be marked as such

-Provision for hand wash and hand sanitisers

-Installation and use of Aarogya Setu app shall be advised to all

-Thermal screening to be carried out. Only asymptomatic individuals shall be allowed.

-Self monitoring of health and reporting any illness

-Staggered show timings shall be followed for different screens

-Digital modes of payments to be encouraged

-Regular cleaning and disinfection of the box office, and other areas

-Sufficient numbers of counters at the box office shall be opened

-Audience encouraged to avoid movement during the intermission

-Floor markers shall be used for physical distancing for queue management at box office

-Purchase of tickets at box office to be open throughout the day, advance booking to be allowed to avoid overcrowding

-Only packaged food and beverages shall be allowed; no delivery inside hall.

-Multiple sale counters for food and beverage.

-Measures for the safety of sanitization of staff such as adequate provision for gloves,boots, masks, PPE, etc.

-Contact number shall be taken to facilitate contact tracing

-Covid-19 related stigmatization or unruly behaviour shall be dealt with strictly.

-Temperature setting of all air conditioning should be in the range of 24-30 degree Celsius

-Public service announcement on wearing masks, physical distancing and hand hygiene to be made before and after screening and during intermission.

Meanwhile, with 3,036 new cases, Delhi’s Covid-19 tally rose to 3.14 lakh, the health department said on Tuesday. The national capital recorded 45 more novel coronavirus deaths, taking the toll to 5,854. The Delhi government has significantly ramped up testing in the past few days. The number of rapid antigen tests conducted on Monday stood at 43,934, while the RT-PCR, CBNAAT and True NAAT tests figures were 11,023, totalling to 54,957, according to the bulletin.

Subscribe to Mint Newsletters

* Enter a valid email

* Thank you for subscribing to our newsletter.

Read more

Categories
Livemint news News in India

India’s covid-19 active caseload below 9 lakh for sixth consecutive day as recoveries rise – News in India by Post24x7

2020-10-14 09:43:00
Coronavirus

India’s COVID-19 recoveries have surged to over 63 lakh, while active cases of coronavirus infection remained below nine lakh for the sixth consecutive day, the Union Health Ministry said on Wednesday.

The total recoveries have increased to 63,019,27. A total of 730 deaths were reported in the last 24 hours. Till date, a total of 11,0586 deaths are reported in the country. The fatality rate stands at 1.53%

Also, a total of 74,632 patients have recovered and were discharged in a span of 24 hours against 63,509 new infections reported during the same period.

“India continues to report a trend of steadily decreasing active cases.For the fourth day after the active cases dropped below the 9 lakh mark after a month, the decline continues,” the ministry said.

There are 82,68, 76 active cases of coronavirus infection in the country, according to the data updated at 8 am. The national recovery rate has progressed to 87.05%, the ministry said.

The ministry said that 77 per cent of the new recovered cases are observed to be concentrated in 10 states and UTs .

Maharashtra and Karnataka contribute more than 10,000 to the single-day recovery, it said.

Also, 81 per cent of the 66,732 fresh COVID-19 cases recorded in a span of 24 hours are from 10 states and UTs, the ministry said.

Subscribe to Mint Newsletters

* Enter a valid email

* Thank you for subscribing to our newsletter.

Read more

Categories
Livemint news News in India

Funds won’t be a constraint for coronavirus vaccination: Expenditure secretary – News in India by Post24x7

2020-10-13 20:40:00
Coronavirus

Budgetary resources will not be a constraint in vaccinating the needy for the coronavirus disease, expenditure secretary T.V. Somanathan told Mint in an interview on Tuesday, as government plans to vaccinate 20-25 crore Indians by July next year.

“Finance ministry will ensure that availability of resources is not a reason for non-vaccination. Once proven vaccines are available, we will definitely make resources available; that is our responsibility and it will be done,” Somanathan said.

Serum Institute of India chief executive officer Adar Poonawalla in September stirred a controversy by claiming that the government may need 80,000 crore over the next one year for distribution of Covid-19 vaccine to every person in India, calling it a “concerning challenge”. However, health secretary Ajay Bhushan later disagreed with that high estimate.

“I have seen reports saying ‘Oh, how the government will fund it!’ We are not a banana republic. We can afford to pay for the vaccine. We will find the money, we will somehow manage,” Somanathan said, without revealing how much exactly government may spend on vaccination.

Asked whether the vaccination will be free of cost for all citizens, Somanathan said he didn’t mean that. “Those matters health ministry will decide and strictly I am not commenting on that. What I am saying is there won’t be any budgetary stringency affecting vaccination. I am not necessarily saying it will be free. Whether people who can afford should pay or not is a separate issue. Certainly those who need vaccine and cannot (pay), government will ensure that they get it. Sometimes when you don’t charge, it is abused. It is diverted to commercial market. So we have to be careful,” he added.

To counter vaccine nationalism and reduce price of covid-19 vaccines, India along with South Africa has approached the World Trade Organisation seeking waiver of patent conditionalities on coronavirus related medicines. The matter is likely to be discussed later this week.

Harsh Vardhan on Tuesday said India will have a vaccine for novel coronavirus from more than one source by early next year. “We’re expecting that early next year we should have vaccine in the country from maybe more than one source. Our expert groups are formulating strategies to plan on how to roll out the distribution of the vaccine in the country,” News agency ANI tweeted quoting the minister.

Earlier this month, Harsh Vardhan had said the government plans to administer around 40-50 crore Covid-19 vaccines to 20-25 crore Indians by July adding that the Centre, along with states, is also preparing a list of priority population groups, especially frontline health workers, who would receive immunisation shots.

Covid-19 vaccines currently undergoing trial in India are 2 dose and 3 dose vaccines. Vaccine by Serum Institute of India and Bharat Biotech require 2 doses while the Cadila Healthcare vaccine requires 3 doses. For other vaccines in pre-clinical stages, the dosing is being tested.

Currently, two indigenously-developed vaccine candidates, one by Bharat Biotech in collaboration with ICMR and the other by Zydus Cadila Ltd, are in phase 2 of the human clinical trials.

Pune-based Serum Institute of India, which has partnered with AstraZeneca for manufacturing the Oxford Covid-19 vaccine candidate also, is conducting phase 2 and 3 human clinical trials of the candidate in India.

Subscribe to Mint Newsletters

* Enter a valid email

* Thank you for subscribing to our newsletter.

Read more

Categories
Livemint news News in India

Policyholders can now renew Corona Rakshak, Kavach plans till March 2021 – News in India by Post24x7

2020-10-13 19:41:00
Coronavirus

The regulator in June 2020 had allowed insurance companies to offer standard benefit-based and standard indemnity covid-19 health policies.

The fixed-benefit policy called Corona Rakshak Policy entails a lump sum benefit equal to 100% of the sum insured if the policyholder tests positive for covid-19 and requires hospitalization for a minimum period of 72 hours. On payment of 100% of sum insured the policy shall be terminated.

The indemnity policy called Corona Kavach Policy has a base cover with a cap on the sum insured of up to 5 lakh. The minimum sum insured was 50,000 and policyholders can opt for a cover in multiples of 50,000, up to 5 lakh.

Both these policies have a tenure of 3.5 months, 6.5 months or 9.5 months.

Welcome the Irdai’s move, Gurdeep Singh Batra, head-retail underwriting, Bajaj Allianz General Insurance, said: “The covid-19 vaccine is yet to come out and the purpose of these policies is to mainly cover the treatment costs against immediate health risks that people face due to the pandemic. Since its launch, the covid-19 specific health policies have gained really good traction mainly due it’s short term coverage been looked at immediately.”

While releasing the guidelines in June, Irdai had specified that lifelong renewability, migration and portability were not applicable to these products. It has now modified these guidelines.

The policies can now be extended for further terms of 3.5 months, 6.5 months or 9.5 months, with maximum renewal allowed till 31 March 2021. According to the regulator, the renewal can only be done only before the expiry of the existing policy contract, and if the policy is renewed, an additional waiting period of 15 days will not be imposed.

Insurers have also been allowed to change sum insured by the policyholder. For any increase in the sum insured, the waiting period shall start afresh only for the enhanced portion of the sum insured.

For migration of Corona Kavach (individual policies), insurers have the choice to offer migration to any other indemnity-based health insurance product offered by them.

For group Corona Kavach policies, insurers can offer migration to any other individual indemnity-based policy at the point of exit of the policyholder from the group policy or the cessation of coverage.

On portability, Irdai said that general and health insurers can port Corona Kavach (individual) policy from one insurer to another. The accrued gains of waiting period served in the existing Corona Kavach policy shall be protected in respect of coverage of Covid-19, by the porting-in insurer.

For Corona Kavach policy (group or individual), migration or portability to any other comprehensive health insurance policy has also been allowed, till the end of the policy period.

According to experts, it is better to go for a policy that covers all kinds of hospitalization as it could come up for various reasons and not just covid-19.

“We would prefer that such insuring population eventually opts for comprehensive health insurance policies, after realizing the important role that health insurance plays in times of such exigencies and future complications,” said Batra.

Subscribe to Mint Newsletters

* Enter a valid email

* Thank you for subscribing to our newsletter.

Read more

Categories
Livemint news News in India

47% of covid deaths registered among those aged below 60 years: Health Ministry – News in India by Post24x7

2020-10-13 18:09:00
Coronavirus

NEW DELHI :
About 47% of COVID-19 deaths have been recorded among those aged below 60 years, the Health Ministry said on Tuesday.

Addressing a press briefing, Health Ministry Secretary Rajesh Bhushan said about 70% COVID-19 deaths have been of male patients while 30% of fatalities from the infection has been reported in females.

“About 53% COVID-19 deaths registered among those aged 60 and above, 35% in 45-60 years, 10% in 26-44 years and 1% each in the age-group 18-25 years and below 17 years,” Bhushan said.

Providing data on case fatality rate among different age groups – with and without comorbidities, he said in the age group of 60 years and above, 24.6% of deaths were of people with comorbidities while 4.8% were of those without comorbidities.

In the age group of 45-60 years, 13.9% of deaths were of patients with comorbidities while 1.5% were of those without comorbidities, he said.

In the age group of less than 45 years, people with comorbidities constituted 8.8% of deaths while 0.2% didn’t have any comorbidities, he said.

The overall case fatality rate of people with comorbidities stood at 17.9% and 1.2% for those without comorbidities.

Bhushan further said there has been decline in the cumulative, weekly and daily COVID-19 positivity rates which stand at 8.07%, 6.24% and 5.16% respectively.

“Average daily COVID-19 positivity rate has declined from 8.50% between September 9-September 15 to 6.24% between October 7-October 13,” he added.

He further said there are 8,38,729 active cases in the country as on date and they have been below the nine lakh mark for the fifth consecutive day.

Presenting the data, Bhushan said there is “significant increase” in testing for COVID-19 and there is also continuous decline in positivity rate.

Subscribe to Mint Newsletters

* Enter a valid email

* Thank you for subscribing to our newsletter.

Read more

Categories
Livemint news News in India

Weekly Covid-19 positivity rate sharply declines to 6.24% from 8.5%: Govt – News in India by Post24x7

2020-10-13 16:54:00
Coronavirus

The health ministry Tuesday said there was a decline in cumulative, weekly and daily COVID-19 positivity rates. They now stand at 8.07%, 6.24% and 5.16% respectively, it added.

The ministry in its press briefing told reporters that the average daily COVID-19 positivity rate has declined from 8.50% between September 9 and September 15 to 6.2% between 7 and 13 October.

The ministry also highlighted that 14 States and Union Territories have higher Test Per Million and lower positivity rate than India average.

Speaking on the current situation of the novel coronavirus pandemic, it further said there are 8,38,729 active cases in the country as on date. The number has been below the 9 lakh-mark for the fifth consecutive day. More than half, about 53% of COVID-19 deaths are of patients aged 60 and above, about 35% deaths are of patients in 45-60 yrs age group and 10% in 26-44 yrs age group, the ministry added.

India’s COVID-19 recoveries crossed 62 lakh today; highest in the world, the ministry added.

“Around 87% of people have been discharge or cured. There are 11.69% active cases who are either in hospitals or under home isolation and 1.53% are death cases,” noted Rajesh Bhushan, Secretary, Union Health Ministry.

The percentage of active cases in the country is 11.69%. 10 states account for 79% of total active COVID cases in the country. Out of this, 11.26% are in Kerala, 25.38% are in Maharashtra and 13% are in Karnataka. “We are conducting discussions with these states to figure out a way to curb the COVID-19 cases.” added Bhushan.

Underlining the Covid-19 safety protocols, the government also mentioned the intensive campaign for COVID appropriate behaviour.

“We have decided to launch an intensive campaign, ‘Jan Andolan for COVID-19 Appropriate Behaviour’ for two months, October and November, and then it will continue in various forms till March,” said Amit Khare, Secretary, Ministry of Information and Broadcasting.

“There is stabilisation in the impact of COVID-19. We have to be more careful in our hygiene practices as it is a respiratory virus and most respiratory viruses escalate during winter. Behavioral change is necessary, masks are mandatory, said Dr. VK Paul, Member (Health), NITI Aayog.

Subscribe to Mint Newsletters

* Enter a valid email

* Thank you for subscribing to our newsletter.

Read more